Landos Biopharma, Inc.
LABP · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $18,000 | $0 |
| % Growth | – | -100% | – | – |
| Cost of Goods Sold | $0 | $577 | $196 | $137 |
| Gross Profit | $0 | -$577 | $17,804 | -$137 |
| % Margin | – | – | 98.9% | – |
| R&D Expenses | $11,999 | $25,680 | $41,564 | $25,338 |
| G&A Expenses | $10,728 | $14,881 | $15,252 | $5,338 |
| SG&A Expenses | $10,728 | $14,881 | $15,252 | $5,338 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $1,285 | $394 | $0 |
| Operating Expenses | $22,727 | $40,561 | $56,816 | $30,676 |
| Operating Income | -$22,727 | -$40,561 | -$38,816 | -$30,676 |
| % Margin | – | – | -215.6% | – |
| Other Income/Exp. Net | $792 | $1,285 | $394 | $532 |
| Pre-Tax Income | -$21,935 | -$39,276 | -$38,422 | -$30,144 |
| Tax Expense | $0 | -$1,285 | -$196 | $0 |
| Net Income | -$21,935 | -$37,991 | -$38,226 | -$30,144 |
| % Margin | – | – | -212.4% | – |
| EPS | -3.5 | -9.44 | -9.5 | -7.51 |
| % Growth | 62.9% | 0.6% | -26.5% | – |
| EPS Diluted | -3.5 | -9.44 | -9.5 | -7.51 |
| Weighted Avg Shares Out | 6,276 | 4,025 | 4,025 | 4,012 |
| Weighted Avg Shares Out Dil | 6,276 | 4,025 | 4,025 | 4,012 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $412 | $455 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $44 | $577 | $196 | $592 |
| EBITDA | -$22,683 | -$39,276 | -$38,620 | -$30,084 |
| % Margin | – | – | -214.6% | – |